Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 17, Status: Authorised
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):